Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index

Liver International

Volumn 37, Issue 3, 2017, Pages 369-376

  Bachofner, Jacqueline A ^a   Valli, Piero V ^a   Kröger, Arne ^a   Bergamin, Irina ^b   Künzler, Patrizia ^b   Baserga, Adriana ^c   Braun, Dominique ^a,d   Seifert, Burkhardt ^d   Moncsek, Anja ^a   Fehr, Jan ^a   Semela, David ^b   Magenta, Lorenzo ^c   Müllhaupt, Beat ^a   Terziroli Beretta Piccoli, Benedetta ^c   Mertens, Joachim C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Department of Neurosurgery   (Switzerland)

^c Epatocentro Ticino   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

APRI; chronic hepatitis C; DAA; FIB 4; liver fibrosis; SVR; transient elastography

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; DACLATASVIR; DASABUVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ASPARTATE AMINOTRANSFERASE;

ADULT; ANALYTICAL PARAMETERS; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE PLATELET RATIO; CHRONIC HEPATITIS C; COHORT ANALYSIS; FEMALE; FIBROSIS 4 SCORE; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON INVASIVE PROCEDURE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SCORING SYSTEM; SUSTAINED VIROLOGIC RESPONSE; TRANSIENT ELASTOGRAPHY; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; CYTOLOGY; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; ELASTOGRAPHY; HEPACIVIRUS; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX; SWITZERLAND; THROMBOCYTE; VIROLOGY;

ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; BLOOD PLATELETS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUSTAINED VIROLOGIC RESPONSE; SWITZERLAND;

EID: 84996564330     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13256     Document Type: Article

References (23)

1. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47–57.
2. European Association for Study of L. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
3. PANEL A I H G. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.
4. European Association for Study of L, Asociacion Latinoamericana Para El Estudio Del H. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–264.
5. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–1713.
6. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960–974.
7. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013–1021.
8. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med. 2013;159:372.
9. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol. 1999;30:783–787.
10. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517–524.
11. European Association for the Study of the L, European Organisation for R, Treatment of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908–943.
12. Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230–236.
13. Lee HW, Chon YE, Kim SU, et al. Predicting liver-related events using transient elastography in chronic hepatitis C patients with sustained virological response. Gut Liv. 2016;10:429–436.
14. Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther. 2016;43:16–29.
15. Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692–699.
16. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847.
17. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293–1302.e4.
18. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients. Hepatology. 2016;64:405–414.
19. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53:726–736.
20. Njei B, McCarty TR, Luk J, Ewelukwa O, Ditah I, Lim JK. Use of transient elastography in patients with HIV-HCV co-infection: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016; 31:1684–1693.
21. Asrani SK, Talwalkar JA, Kamath PS, et al. Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol. 2014;60:934–939.
22. Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015;13:440–451.e6.
23. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325.